EGFR and non-small cell lung carcinoma: In this study, lazertinib showed substantial CNS activity in treating intracranial metastases in patients with EGFR-variant NSCLC, suggesting it could be an alternative to brain local treatment for those who progressed after prior EGFR TKIs.